

Annex C: Gavi 5.0 Strategy Indicator Dashboard

## Gavi 5.0 Mission and Strategy Performance Indicators (Proposed)

Mission	<b>M.1 Under-five mortality rate (SDG 3.2.1)<sup>o</sup></b> <b>M.2 Future deaths averted<sup>o</sup></b> <b>M.3 Future DALYs averted<sup>o</sup></b>				<b>M.4 Reduction in zero-dose children (Equity indicator)<sup>**</sup></b> <b>M.5 Unique children immunized<sup>o</sup></b> <b>M.6 Economic benefits unlocked<sup>o</sup></b>			
Goals	<b>INTRODUCE AND SCALE UP VACCINES</b>		<b>STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNISATION</b>		<b>IMPROVE SUSTAINABILITY OF IMMUNISATION PROGRAMMES</b>		<b>ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTS</b>	
Strategy performance	<b>S1.1 Breadth of protection*</b> S1.2 SDG 3.b.1 (DTP3, MCV2, PCV3, HPV coverage)** S1.3 Rate of scale up of new vaccines <sup>o</sup> S1.4 Vaccine introductions* S1.5 Country prioritisation of vaccines*  <b>S1.6 Preventive campaign reach (measles)<sup>o</sup></b>  <b>S1.7 Timely outbreak detection and response**</b>		<b>S2.1 Geographic equity DTP3 coverage**</b> <b>S2.2 DTP drop-out**</b> <b>S2.3 MCV1 coverage<sup>o</sup></b> S2.4 Number of immunisation sessions <sup>o</sup> S2.5 Stock availability at facility level** S2.6 EPI management capacity* S2.7 Percentage of countries implementing tailored plans to overcome demand barriers** S2.8 Percentage of countries addressing gender-related barriers with Gavi support <sup>o</sup>		<b>S3.1 Co-financing fulfillment*</b> <b>S3.2 Preventing backsliding in routine immunisation coverage in Gavi-transitioned countries<sup>+, o</sup></b> <b>S3.3 (If applicable) Vaccine introductions (HPV, PCV, Rota) catalyzed in Gavi-transitioned and never-Gavi eligible countries<sup>+, o</sup></b>  <i>+ MICs strategy applicable to former and select never-Gavi eligible countries has not yet been reviewed and approved by PPC and the Board</i>		<b>S4.1 Number of markets exhibiting acceptable supply dynamics**</b>  <b>S4.2 Number of innovative products within the pipeline with commercial-scale manufacturers<sup>o</sup></b>  <b>S4.3 Number of vaccine and immunisation-related products with improved characteristics procured<sup>o</sup></b>	

Alignment with Global IA2030 M&E indicators

\*\* full alignment (8)

\* alignment with differences due to Gavi context (6)

! not aligned (0)

o not included in IA2030 (12)